VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection

Journal of Clinical Pathology

Volumn 62, Issue 5, 2009, Pages 448-454

  Engels, Knut ^a   Du Bois, A ^b   Harter, P ^b   Fisseler Eckhoff, A ^b   Kommoss, F ^c   Stauber, R ^d   Kaufmann, M ^a   Nekljudova, V ^e   Loibl, S ^a,e  

^a GOETHE UNIVERSITY   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c Pathological Institute   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e GBG Forschungs GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CARBOPLATIN; CD34 ANTIBODY; EPIRUBICIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; TOPOTECAN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR SYSTEM; CELL DENSITY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66349096698     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.063859     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Jahn I, Eberle A, Niehues C, et al. Gebärmuttererkrankungen. Berlin: Robert Koch Institut, 2007.
3. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329
4. Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74.
5. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739 (Pubitemid 37328908)
6. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436 (Pubitemid 38745528)
7. Semenza GL. A new weapon for attacking tumour blood vessels. N Engl J Med 2008;358:2066-2067
8. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-534 (Pubitemid 43980541)
9. Ridnour LA, Thomas DD, Donzelli S, et al. The biphasic nature of nitric oxide responses in tumour biology. Antioxid Redox Signal 2006;8:1329-1337 (Pubitemid 44182431)
10. Engels K, Knauer SK, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007;211:532-540 (Pubitemid 46502429)
11. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995;177:275-283
12. Suhonen KA, Anttila MA, Sillanpaa SM, et al. Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer. Eur J Cancer 2007;43:1300-1307 (Pubitemid 46720248)
13. Engels K, Knauer SK, Loibl S, et al. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 2008;68:5159-5166
14. Hartenbach EM, Olson TA, Goswitz JJ, et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 199723;121:169-175 (Pubitemid 28008916)
15. Nakanishi Y, Kodama J, Yoshinouchi M, et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 1997;16:256-262 (Pubitemid 27282300)
16. Orre M, Rogers PA. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer 1999;84:101-108 (Pubitemid 29133818)
17. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-1579
18. Goodheart MJ, Vasef MA, Sood AK, et al. Ovarian cancer p53 mutation is associated with tumour microvessel density. Gynecol Oncol 2002;86:85-90. (Pubitemid 34757056)
19. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996;69:205-211 (Pubitemid 26233300)
20. Gadducci A, Viacava P, Cosio S, et al. Intratumoural microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res 2003;23:549-556 (Pubitemid 36358449)
21. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-680 (Pubitemid 40216420)
22. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508 (Pubitemid 46243494)
23. Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 2007;7:1339-1345
24. Raspollini MR, Amunni G, Villanucci A, et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004;14:815-823 (Pubitemid 39238165)
25. Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83:196-203. (Pubitemid 30411717)
26. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006;16(Suppl 1):241-246
27. Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 200815;14:3030-3035
28. Shimogai R, Kigawa J, Itamochi H, et al. Expression of hypoxia-inducible factor 1α gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 2008;18:499-505.
29. Senger DR, Galli SJ, Dvorak AM, et al. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985
30. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-187 (Pubitemid 29031373)
31. Tempfer C, Obermair A, Hefler L, et al. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998;92:360-363 (Pubitemid 28396857)
32. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613 (Pubitemid 26272112)
33. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-643
34. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684 (Pubitemid 36749216)
35. Osada R, Horiuchi A, Kikuchi N, et al. Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007;38:1310-1320 (Pubitemid 47247486)
36. Nakai H, Watanabe Y, Ueda H, et al. Hypoxia inducible factor 1-α expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett 2007;251:164-167 (Pubitemid 46589775)
37. Melillo G, Musso T, Sica A, et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-1693
38. Ambs S, Merriam WG, Bennett WP, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumour angiogenesis and colon cancer progression. Cancer Res 1998;58:334-341 (Pubitemid 28047076)
39. Yamaguchi K, Saito H, Oro S, et al. Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma. Oncology 2005;68:471-478 (Pubitemid 41160979)
40. Ichinoe M, Mikami T, Shiraishi H, et al. High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas. Histopathology 2004;45:612-618 (Pubitemid 40029821)
41. Raspollini MR, Amunni G, Villanucci A, et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 2004;92:806-812 (Pubitemid 38251381)